Baird's Brian Skorney on Jazz Pharmaceuticals (JAZZ): 'We are buyers on weakness'
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated an Underperform rating and $209.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ).The analyst comments "Positive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
